Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 0.3 %

AKTX stock opened at $1.08 on Friday. Akari Therapeutics has a 12-month low of $0.90 and a 12-month high of $4.40. The company has a 50 day moving average of $1.15 and a two-hundred day moving average of $2.19.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.